-
公开(公告)号:US07238693B2
公开(公告)日:2007-07-03
申请号:US10467932
申请日:2002-02-22
申请人: Eric Nicolai , Sophie Curtet , James Sicsic , Frank Lezoualc'h , Rodolphe Fischmeister , Michel Langlois , Magali Maillet , Michèle Launay
发明人: Eric Nicolai , Sophie Curtet , James Sicsic , Frank Lezoualc'h , Rodolphe Fischmeister , Michel Langlois , Magali Maillet , Michèle Launay
IPC分类号: A61K31/501 , A61K31/496 , C07D401/04 , C07D403/04 , A61K31/495 , C07D295/15
CPC分类号: C07D213/74 , C07D213/79 , C07D213/84 , C07D237/20 , C07D239/42 , C07D241/20 , C07D285/10 , C07D295/088 , C07D333/42 , C07D401/04 , C07D403/04
摘要: The present invention relates to novel compounds, the preparation and use, particularly therapeutic, thereof. More specifically, it relates to compounds derived from aryl carbamates, the preparation and use thereof, particularly in the field of human and animal health. The compounds according to the invention are preferably 5-HT4 serotoninergic receptor ligands and can therefore be used in the therapeutic or prophylactic treatment of any disorder involving a 5-HT4 receptor. The invention also relates to pharmaceutical compositions comprising such compounds, the preparation and use thereof and treatment methods using said compounds. Compounds according to the invention include compounds of the following formula (I):
摘要翻译: 本发明涉及新化合物,其制备和用途,特别是其治疗方法。 更具体地说,它涉及衍生自芳基氨基甲酸酯的化合物,其制备和用途,特别是在人和动物健康领域。 根据本发明的化合物优选为5-HT 4 5-羟色胺能受体配体,因此可用于治疗或预防治疗涉及5-HT 4受体的任何疾病 。 本发明还涉及包含这些化合物的药物组合物,其制备和用途以及使用所述化合物的治疗方法。 根据本发明的化合物包括下式(I)的化合物: